Imperial College London

DrCharaStavraka

Faculty of MedicineDepartment of Surgery & Cancer

 
 
 
//

Contact

 

chara.stavraka09

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

56 results found

McCraw AJ, Chauhan J, Bax HJ, Stavraka C, Osborn G, Grandits M, López-Abente J, Josephs DH, Spicer J, Wagner GK, Karagiannis SN, Chenoweth A, Crescioli Set al., 2021, Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments., Cancers (Basel), Vol: 13, ISSN: 2072-6694

IgE, the predominant antibody class of the allergic response, is known for its roles in protecting against parasites; however, a growing body of evidence indicates a significant role for IgE and its associated effector cells in tumour immunosurveillance, highlighted by the field of AllergoOncology and the successes of the first-in-class IgE cancer therapeutic MOv18. Supporting this concept, substantial epidemiological data ascribe potential roles for IgE, allergy, and atopy in protecting against specific tumour types, with a corresponding increased cancer risk associated with IgE immunodeficiency. Here, we consider how epidemiological data in combination with functional data reveals a complex interplay of IgE and allergy with cancer, which cannot be explained solely by one of the existing conventional hypotheses. We furthermore discuss how, in turn, such data may be used to inform future therapeutic approaches, including the clinical management of different patient groups. With epidemiological findings highlighting several high-risk cancer types protected against by high IgE levels, it is possible that use of IgE-based therapeutics for a range of malignant indications may offer efficacy to complement that of established IgG-class antibodies.

Journal article

Naqash AR, Kihn-Alarcon AJ, Stavraka C, Kerrigan K, Vareki SM, Pinato DJ, Puri Set al., 2021, The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer, Annals of Translational Medicine, Vol: 9, Pages: 1-11, ISSN: 2305-5839

Immunotherapy has led to a paradigm shift in the treatment of several cancers. There have been significant efforts to identify biomarkers that can predict response and toxicities related to immune checkpoint inhibitor (ICPI) therapy. Despite these advances, it has been challenging to tease out why a subset of patients benefit more than others or why certain patients experience immune-related adverse events (irAEs). Although the immune-modulating properties of the human gut bacterial ecosystem are yet to be fully elucidated, there has been growing interest in evaluating the role of the gut microbiome in shaping the therapeutic response to cancer immunotherapy. Considerable research efforts are currently directed to utilizing metagenomic and metabolic profiling of stool microbiota in patients on ICPI-based therapies. Dysbiosis or loss of microbial diversity has been associated with a poor treatment response to ICPIs and worse survival outcomes in cancer patients. Emerging data have shown that certain bacterial strains, such as Faecalibacterium that confer sensitivity to ICPI, also have a higher propensity to increase the risk of irAEs. Additionally, the microbiome can modulate the local immune response at the intestinal interface and influence the trafficking of bacterial peptide primed T-cells distally, influencing the toxicity patterns to ICPI. Antibiotic or diet induced alterations in composition of the microbiome can also indirectly alter the production of certain bacterial metabolites such as deoxycholate and short chain fatty acids that can influence the anti-tumor tolerogenesis. Gaining sufficient understanding of the exact mechanisms underpinning the interplay between ICPI induced anti-tumor immunity and the immune modulatory role gut microbiome can be vital in identifying potential avenues of improving outcomes to cancer immunotherapy. In the current review, we have summarized and highlighted the key emerging data supporting the role of gut microbiome in regu

Journal article

Chauhan J, McCraw AJ, Nakamura M, Osborn G, Sow HS, Cox VF, Stavraka C, Josephs DH, Spicer JF, Karagiannis SN, Bax HJet al., 2020, IgE Antibodies against Cancer: Efficacy and Safety, ANTIBODIES, Vol: 9

Journal article

Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa Let al., 2020, Biliary tract cancers: molecular heterogeneity and new treatment options, Cancers, Vol: 12, Pages: 1-17, ISSN: 2072-6694

Most patients with biliary tract cancer (BTC) are diagnosed with advanced disease, relapse rates are high in those undergoing surgery and prognosis remains poor, while the incidence is increasing. Treatment options are limited, and chemotherapy is still the standard of care in both adjuvant and advanced disease setting. In recent years, different subtypes of BTC have been defined depending on the anatomical location and genetic and/or epigenetic aberrations. Especially for intrahepatic cholangiocarcinoma (iCCA) novel therapeutic targets have been identified, including fibroblast growth factor receptor 2 gene fusions and isocitrate dehydrogenase 1 and 2 mutations, with molecularly targeted agents having shown evidence of activity in this subgroup of patients. Additionally, other pathways are being evaluated in both iCCA and other subtypes of BTC, alongside targeting of the immune microenvironment. The growing knowledge of BTC biology and molecular heterogeneity has paved the way for the development of new therapeutic approaches that will completely change the treatment paradigm for this disease in the near future. This review provides an overview of the molecular heterogeneity of BTC and summarizes new targets and emerging therapies in development. We also discuss resistance mechanisms, open issues, and future perspectives in the management of BTC.

Journal article

Nakamura M, Souri EA, Osborn G, Laddach R, Chauhan J, Stavraka C, Lombardi S, Black A, Khiabany A, Khair DO, Figini M, Winship A, Ghosh S, Montes A, Spicer JF, Bax HJ, Josephs DH, Lacy KE, Tsoka S, Karagiannis SNet al., 2020, IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype, CANCERS, Vol: 12

Journal article

Pouptsis A, Swafe L, Patwardhan M, Stavraka Cet al., 2020, Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations, FRONTIERS IN ONCOLOGY, Vol: 10, ISSN: 2234-943X

Journal article

Bax HJ, Chauhan J, Stavraka C, Khiabany A, Pellizzari G, Hak CWC, Robinson A, Ilieva KM, Woodman N, Naceur-Lombardelli C, Gillett C, Pinder S, Gould HJ, Corrigan CJ, Till SJ, Katugampola S, Barton C, Winship A, Ghosh S, Montes A, Josephs DH, Spicer JF, Karagiannis SNet al., 2020, AllergoOncology: Study of potential hypersensitivity to an anti-tumor IgE therapeutic candidate in a diverse cohort of ovarian cancer patients using a basophil activation test, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 186-187, ISSN: 0105-4538

Conference paper

Bax HJ, Khiabany A, Stavraka C, Pellizzari G, Hak CCW, Robinson A, Ilieva KM, Woodman N, Naceur-Lombardelli C, Gillett C, Pinder S, Gould HJ, Corrigan CJ, Till SJ, Katugampola S, Barton C, Winship A, Ghosh S, Montes A, Josephs DH, Spicer JF, Karagiannis SNet al., 2020, Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate, ALLERGY, Vol: 75, Pages: 2069-+, ISSN: 0105-4538

Journal article

Chrysovergis A, Papanikolaou V, Mastronikolis N, Tsiambas E, Ragos V, Peschos D, Riziotis C, Stavraka C, Roukas D, Kyrodimos Eet al., 2020, Chromosome 17 In Situ Hybridization Grid-based Analysis in Oral Squamous Cell Carcinoma, ANTICANCER RESEARCH, Vol: 40, Pages: 3759-3764, ISSN: 0250-7005

Journal article

Kyrodimos E, Chrysovergis A, Mastronikolis N, Tsiambas E, Riziotis C, Roukas D, Fotiades P, Stavraka C, Ragos V, Paschopoulos M, Papanikolaou Vet al., 2020, Impact of Chromosome 9 Numerical Imbalances in Oral Squamous Cell Carcinoma: A Pilot Grid-Based Centromere Analysis, DIAGNOSTICS, Vol: 10

Journal article

Bax HJ, Chauhan J, Stavraka C, Khiabany A, Nakamura M, Pellizzari G, Ilieva KM, Lombardi S, Gould HJ, Corrigan CJ, Till SJ, Katugampola S, Jones PS, Barton C, Winship A, Ghosh S, Montes A, Josephs DH, Spicer JF, Karagiannis SNet al., 2020, Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome, CELLS, Vol: 9

Journal article

Galanis N, Stavraka C, Agathangelidis F, Petsatodis E, Giankoulof C, Givissis Pet al., 2020, Coagulopathy in COVID-19 infection: a case of acute upper limb ischemia, JOURNAL OF SURGICAL CASE REPORTS, ISSN: 2042-8812

Journal article

Metaxas G, Tsiambas E, Kavantzas N, Stavraka C, Patsouris E, Lazaris AC, Thomopoulou GEet al., 2020, Impact of Cyclin D1 deregulation in HPV-mediated squamous intraepithelial lesions based on cell spots analysis, JOURNAL OF BUON, Vol: 25, Pages: 792-796, ISSN: 1107-0625

Journal article

Stavraka C, Evans TRJ, Dunlop J, Earl H, Cameron DA, Coleman RE, Perren T, Leonard RCF, Mansi JLet al., 2020, 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study, 42nd Annual San Antonio Breast Cancer Symposium, Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472

Conference paper

Papanikolaou V, Chrysovergis A, Mastronikolis N, Tsiambas E, Ragos V, Peschos D, Stavraka C, Roukas D, Kyrodimos Eet al., 2020, y Topoisomerase IIa Protein Expression Patterns in Laryngeal Squamous Cell Carcinoma, ANTICANCER RESEARCH, Vol: 40, Pages: 807-811, ISSN: 0250-7005

Journal article

Ilieva KM, Fazekas-Singer J, Bax HJ, Crescioli S, Montero-Morales L, Mele S, Sow HS, Stavraka C, Josephs DH, Spicer JF, Steinkellner H, Jensen-Jarolim E, Tutt ANJ, Karagiannis SNet al., 2019, AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody, ALLERGY, Vol: 74, Pages: 1985-1989, ISSN: 0105-4538

Journal article

Stavraka C, Pouptsis A, Synowiec A, Aggelis V, Satterthwaite L, Khan S, Chauhan M, Holden CE, Young S, Karampera C, Martinou M, Mills-Baldock T, Baxter M, Eccles BK, Iveson TJ, Shiu K-K, Hill ME, Abdel-Raouf S, Thomas A, Ross PJet al., 2019, Trifluridine/tipiracil in metastatic colorectal cancer: An updated multicentre real-world analysis on efficacy, safety and predictive factors, 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: OXFORD UNIV PRESS, Pages: 226-226, ISSN: 0923-7534

Conference paper

Bax HJ, Josephs DH, Stavraka C, Khiabany A, Katugampola S, Jones P, Barton C, Lentfer H, Pellizzari G, Ilieva K, Gould HJ, Corrigan C, Winship A, Ghosh S, Montes A, Spicer JF, Karagiannis SNet al., 2019, Allergooncology: The basophil activation test to monitor hypersensitivity to an anti-cancer IgE undergoing first-in-class, first-in-man clinical trial, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 125-125, ISSN: 0105-4538

Conference paper

Chrysovergis A, Papanikolaou V, Tsiambas E, Stavraka C, Ragos V, Peschos D, Psyrri A, Mastronikolis N, Kyrodimos Eet al., 2019, P53/MDM2 Co-Expression in Laryngeal Squamous Cell Carcinoma Based on Digital Image Analysis, ANTICANCER RESEARCH, Vol: 39, Pages: 4137-4142, ISSN: 0250-7005

Journal article

Stavraka C, Kopeika J, Reddy N, Shewbridge A, Sandri I, Mansi Jet al., 2019, Fertility Outcomes in Breast Cancer Survivors: Experience from a Tertiary Breast Cancer Centre within South-East London, Publisher: ELSEVIER SCIENCE LONDON, Pages: E115-E115, ISSN: 0936-6555

Conference paper

Stavraka C, Pouptsis A, Okonta L, De Souza K, Marinaki A, Karapanagiotou E, Papadatos-Pastos D, Mansi Jet al., 2019, Pretreatment DPYD Genotyping Reduces the Risk of Capecitabine-associated Severe Toxicities: a Prospective Validation Study, Publisher: ELSEVIER SCIENCE LONDON, Pages: E114-E115, ISSN: 0936-6555

Conference paper

Stavraka C, Pouptsis A, Okonta L, DeSouza K, Charlton P, Kapiris M, Marinaki A, Karapanagiotou E, Papadatos-Pastos D, Mansi Jet al., 2019, Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients, Breast Cancer Research and Treatment, Vol: 175, Pages: 511-517, ISSN: 0167-6806

PurposeMetastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities. However, prospective DPYD genotyping has not yet been implemented in routine clinical practice. Following a previous internal review in which two patients underwent lengthy hospitalisations whilst receiving capecitabine, and were subsequently found to be DPD deficient, we initiated routine DPYD genotyping prior to starting capecitabine. This study evaluates the clinical application of routine DPYD screening at a large cancer centre in London.MethodsWe reviewed medical records for consecutive patients with mBC who underwent DPYD genotyping before commencing capecitabine between December 2014 and December 2017. Patients were tested for four DPYD variants associated with reduced DPD activity.ResultsSixty-six patients underwent DPYD testing. Five (8.4%) patients were found to carry DPYD genetic polymorphisms associated with reduced DPD activity; of these, two received dose-reduced capecitabine. Of the 61 patients with DPYD wild-type, 14 (23%) experienced grade 3 toxicities which involved palmar–plantar erythrodysesthesia (65%), and gastrointestinal toxicities (35%); no patient was hospitalised due to toxicity.ConclusionsProspective DPYD genotyping can be successfully implemented in routine clinical practice and can reduce the risk of severe fluoropyrimidine toxicities.

Journal article

Battisti NML, Kingston B, King J, Denton A, Waters S, Sita-Lumsden A, Rehman F, Stavraka C, Kristeleit H, Sawyer E, Houghton D, Davidson N, Howell S, Choy J, Harper P, Roylance R, Fharat R, Mohammed K, Ring A, Johnston Set al., 2019, Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience, BREAST CANCER RESEARCH AND TREATMENT, Vol: 174, Pages: 731-740, ISSN: 0167-6806

Journal article

Stavraka C, Pouptsis A, Kabuubi P, Angelis V, Synowiec A, Baxter M, Barrie A, Costa AA, Nizam A, De Naurois J, Mikropoulos C, Hill M, Graham JS, Harris V, Bridgewater JA, Ross PJet al., 2019, Real-world experience of trifluridine/tipiracil in patients with metastatic colorectal cancer: A multicenter United Kingdom study., Gastrointestinal Cancers Symposium, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X

Conference paper

Battisti NML, Kingston B, King J, Denton A, Waters S, Sita-Lumsden A, Rehman F, Stavraka C, Kristeleit H, Sawyer E, Houghton D, Davidson N, Howell S, Choy J, Harper P, Roylance R, Fharat R, Mohammed K, Ring A, Johnston Set al., 2019, Palbociclib and endocrine therapy in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: The UK compassionate access program experience, San Antonio Breast Cancer Symposium, Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472

Conference paper

Stavraka C, Rush H, Ross P, 2019, Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions, JOURNAL OF HEPATOCELLULAR CARCINOMA, Vol: 6, Pages: 11-21

Journal article

Galanis N, Stavraka C, Valavani E, Kirkos Jet al., 2017, Unsupervised exercise-induced myositis ossificans in the brachialis muscle of a young healthy male: A case report, Orthopaedic Journal of Sports Medicine, Vol: 5, ISSN: 2325-9671

Journal article

Ghazaly EA, Quesne JL, Jiang D, Mangala SL, Chettle J, Rodriguez-Aguayo C, Lopez-Berestein G, Gnanaranjan C, Mura M, Stavraka C, Sood AK, Blagden SPet al., 2017, Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target, Abstracts: AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; October 27-30, 2016; San Francisco, CA, Publisher: American Association for Cancer Research

Conference paper

Stavraka C, Mura M, Fischer R, Thezenas M-L, Maghami SG, Chettle J, Buluwela L, Kessler B, Blagden SPet al., 2017, Abstract B44: Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells, Abstracts: AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; October 27-30, 2016; San Francisco, CA, Publisher: American Association for Cancer Research

Conference paper

Stavraka C, Mura M, Fischer R, Thezenas M-L, Maghami SG, Chettle J, Buluwela L, Kessler B, Blagden SPet al., 2017, Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells, Cancer Research, Vol: 77, Pages: B44-B44, ISSN: 1538-7445

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00607800&limit=30&person=true